Stammdaten
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
Unternehmen & Branche
| Name | OS Therapies Inc |
|---|---|
| Ticker | OSTX |
| CIK | 0001795091 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 68,3 Mio. USD |
| Beta | -2,99 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -28,753,844 | -0.98 | 6,839,534 | -6,095,631 | |
| 2025-09-30 | 10-Q | -6,879,530 | -0.21 | 8,953,251 | 3,637,195 | |
| 2025-06-30 | 10-Q | -4,536,622 | -0.19 | 10,310,475 | 4,943,647 | |
| 2025-03-31 | 10-Q | -3,876,859 | -0.18 | 4,249,931 | -4,186,578 | |
| 2024-12-31 | 10-K | -8,882,938 | -1.28 | 5,538,797 | -3,266,538 | |
| 2024-09-30 | 10-Q | -2,875,232 | -0.18 | 1,977,264 | -707,128 | |
| 2024-06-30 | 10-Q | -1,557,480 | -0.26 | 1,342,221 | -27,063,937 | |
| 2024-03-31 | 10-Q | -1,458,992 | -0.25 | 1,048,924 | -25,506,457 | |
| 2023-12-31 | 10-K | -7,791,582 | -1.46 | 798,082 | -24,016,215 | |
| 2023-09-30 | 10-Q | -1,974,990 | -0.38 | -22,520,397 | ||
| 2023-06-30 | 10-Q | -2,505,057 | -0.47 | -21,271,754 | ||
| 2023-03-31 | 10-Q | -1,846,969 | -18,735,447 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.